3-antigen Staphylococcus aureus vaccine - Pfizer

Drug Profile

3-antigen Staphylococcus aureus vaccine - Pfizer

Alternative Names: 3-antigen Staphylococcus aureus vaccine - Inhibitex/Pfizer; PF-05230894; PF-5230894; SA3Ag; Staph vaccine - Inhibitex/Pfizer; Staphylcoccus aureus vaccine - Inhibitex/Pfizer; Staphylococcus aureus vaccine (3-antigen) - Pfizer; WYE-400062

Latest Information Update: 14 Nov 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 10 Nov 2011 Discontinued - Phase-I for Staphylococcal infections in Australia (IM)
  • 08 Aug 2011 Phase-I/II clinical trials in Staphylococcal infections in USA (IM)
  • 31 Jul 2011 Pfizer completes a phase I trial in healthy volunteers in Australia (NCT01018641)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top